Myra Vision, a Campbell, CA-based developer of a treatment that allows maximum intraocular pressure (IOP) reduction for patients with moderate to severe glaucoma, raised USD25M in Series B funding.
The round was led by Cormorant Asset Management, with participation from The Capital Partnership, the PA MedTech VC Fund and Shifamed angel investors.
Led by Robert Chang, President and CEO, Myra Vision is developing novel technology that is designed to allow safe outflow control to achieve maximum reduction of intraocular pressure (IOP) while also reducing complexity and complication rates.
The company intends to use the funds to further product development, scale manufacturing capabilities, and support first-in-human investigation of its Calibreye System, a novel treatment that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.
It is a privately held portfolio company of Shifamed.
FinSMEs
26/06/2023